A Phase I Study of Oral LOXO-260 in Patients With RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and other Tumors with RET Activation Refractory to Selective RET Inhibitors [131]. Here, RET is linked to medullary thyroid gland carcinoma.